Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol

Autor: Jun Gong, Arsen Osipov, Jeremy Lorber, Mourad Tighiouart, Albert K. Kwan, Hayato Muranaka, Rasaq Akinsola, Sandrine Billet, Abrahm Levi, Anser Abbas, John Davelaar, Neil Bhowmick, Andrew E. Hendifar

Publikováno v: Biomedicines, vol 11, iss 5

Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects against pancreatic ductal ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4879f139bf08e9905294a0c9cd65165
https://escholarship.org/uc/item/3151s7cs

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Autor: Charu Aggarwal, Nabil F. Saba, Alain Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily I. Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, Karl Fraser, Delphine Lissa, Maozhen Gong, Natalia Ceaicovscaia, Amaya Gascó Hernández, Rakesh Kumar

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 29, iss 3

Purpose: Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MED

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30d7dd3b4d6278c10d8b9948e138f327
https://escholarship.org/uc/item/3wz58697

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Autor: Meenal Sinha, Courtney Betts, Li Zhang, Madeline J Griffith, Isabelle Solman, Brandon Chen, Eric Liu, Whitney Tamaki, Jacob Stultz, Jaqueline Marquez, Shamilene Sivagnanam, Alexander Cheung, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Matthew Crocker, Kendra Todd, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Charles D Lopez, Margaret Tempero, Lisa M Coussens, Lawrence Fong

Publikováno v: Journal for immunotherapy of cancer, vol 11, iss 1

BackgroundIn preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine the safety, tolerability, and immunologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2234572939e8210e175f36091a0a956d
https://escholarship.org/uc/item/22n0d044

Lentiviral Gene Therapy for Artemis-Deficient SCID

Autor: Morton J. Cowan, Jason Yu, Janelle Facchino, Carol Fraser-Browne, Ukina Sanford, Misako Kawahara, Jasmeen Dara, Janel Long-Boyle, Jess Oh, Wendy Chan, Shivali Chag, Lori Broderick, Deepak Chellapandian, Hélène Decaluwe, Catherine Golski, Diana Hu, Caroline Y. Kuo, Holly K. Miller, Aleksandra Petrovic, Robert Currier, Joan F. Hilton, Divya Punwani, Christopher C. Dvorak, Harry L. Malech, R. Scott McIvor, Jennifer M. Puck

Publikováno v: The New England journal of medicine, vol 387, iss 25
N Engl J Med

BACKGROUND: The DNA-repair enzyme Artemis is essential for rearrangement of T- and B-cell receptors. Mutations in DCLRE1C, which encodes Artemis, cause Artemis-deficient severe combined immunodeficiency (ART-SCID), which is poorly responsive to allog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4071ee74597de09f3353df2099d10e75
https://escholarship.org/uc/item/0h55w8kq

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Autor: Scott N. Gettinger, Rudolf M. Huber, Dong-Wan Kim, Lyudmila Bazhenova, Karin Holmskov Hansen, Marcello Tiseo, Corey J. Langer, Luis G. Paz-Ares Rodríguez, Howard L. West, Karen L. Reckamp, Glen J. Weiss, Egbert F. Smit, Maximilian J. Hochmair, Sang-We Kim, Myung-Ju Ahn, Edward S. Kim, Harry J.M. Groen, Joanna Pye, Yuyin Liu, Pingkuan Zhang, Florin Vranceanu, D. Ross Camidge

Publikováno v: JTO clinical and research reports, vol 3, iss 9
JTO Clinical and Research Reports, 3(9):100385. Elsevier Inc.
JTO clinical and research reports, 3(9):100385
Gettinger, S N, Huber, R M, Kim, D-W, Bazhenova, L, Hansen, K H, Tiseo, M, Langer, C J, Paz-Ares Rodríguez, L G, West, H L, Reckamp, K L, Weiss, G J, Smit, E F, Hochmair, M J, Kim, S-W, Ahn, M-J, Kim, E S, Groen, H J M, Pye, J, Liu, Y, Zhang, P, Vranceanu, F & Camidge, D R 2022, ' Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC : Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials ', JTO Clinical and Research Reports, vol. 3, no. 9, 100385 . https://doi.org/10.1016/j.jtocrr.2022.100385

Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC.Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f71c967a428eab7259568a9c39a490e5
https://escholarship.org/uc/item/9wr5984c